| Kelsian Group Limited (KLS) ORDINARY FULLY PAID |
Industrials |
$1,188 |
Change of Director's Interest Notice (McArthur)
|
27 Apr 2026 10:38AM |
$3.830 |
$4.375 |
risen by
14.23%
|
|
| Sabre Resources Limited (SBR) ORDINARY FULLY PAID |
Materials |
$4 |
Transformational Copper Gold Acquisition and $2M Placement.
|
27 Apr 2026 10:38AM |
$0.011 |
$0.007 |
fallen by
36.36%
|
|
SBR - Price-sensitive ASX Announcement
Full Release
Key Points
- Sabre Resources to acquire 80% of Brema Resources Pty Ltd.
- Acquisition includes East Tennant Ridge IOCG projects.
- Issuance of milestone shares conditional on resource targets.
- Funding secured until Decision to Mine stage.
- $2 million placement to strengthen financial position.
- Regulatory, shareholder, and third-party approvals needed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Harvest Technology Group Ltd (HTG) ORDINARY FULLY PAID |
Information Technology |
$20 |
Investor Webinar
|
27 Apr 2026 10:37AM |
$0.012 |
$0.013 |
risen by
4.17%
|
|
| Anagenics Limited (AN1) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
AN1 - Appendix 4C & Activity Report for Q3 FY2026
|
27 Apr 2026 10:31AM |
$0.006 |
$0.007 |
risen by
16.67%
|
|
AN1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Anagenics Limited experienced operating cash outflows of $0.3 million in Q3 FY2026, totaling $1.0 million for the nine months ending March 2026.
- The negative cash flow was primarily due to resolving outstanding creditor payments, with anticipated improvements in cash flow expected in the second half of FY2026.
- BLC Cosmetics, a subsidiary of Anagenics, has been restructured and is now trading profitably, with plans to expand its product portfolio.
- York Street Brands' Bouf Haircare, developed using Anagenics' proprietary technology, continued strong performance with royalty revenue of $347,000 in Q3 FY2026.
- Anagenics has invoiced $738,000 in royalty revenue for the nine months ending March 2026.
- The company reported a net cash inflow from financing activities amounting to $924,000 for the quarter.
- Anagenics is focused on growing shareholder value through the global distribution and sales of its proprietary and licensed brands.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kuniko Limited (KNI) ORDINARY FULLY PAID |
Materials |
$6 |
Options Prospectus
|
27 Apr 2026 10:21AM |
$0.042 |
$0.028 |
fallen by
33.33%
|
|
| Raiden Resources Limited (RDN) ORDINARY FULLY PAID |
Materials |
$10 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
27 Apr 2026 10:16AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
RDN - Price-sensitive ASX Announcement
Full Release
Key Points
- Due diligence on Crixás Gold Tailings Project ongoing.
- Environmental licensing process continues.
- Cash balance at $12.33 million as of 31 March 2026.
- Expenditure on exploration activities totaled $296k.
- No mining, production, or development expenses incurred.
- Appendix 5B reports a cash decrease, primarily due to operating losses.
- Exploration and acquisition efforts supported by current cash balance.
- Consideration of divestment or joint venture opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lake Resources NL (LKE) ORDINARY FULLY PAID |
Materials |
$116 |
Notification of cessation of securities - LKE
|
27 Apr 2026 10:14AM |
$0.100 |
$0.050 |
fallen by
50%
|
|
| Lion Selection Group Limited (LSX) ORDINARY FULLY PAID |
Financials |
$123 |
Lion commits to invest $1.6M in Plutonic
|
27 Apr 2026 10:12AM |
$0.905 |
$0.860 |
fallen by
4.97%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Atlas Arteria receives unsolicited Takeover Offer from IFM
|
27 Apr 2026 10:11AM |
$4.330 |
$5.100 |
risen by
17.78%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria received an unsolicited Takeover Offer from IFM.
- The Bidder's Statement from IFM outlines a Takeover Offer to acquire all securities of Atlas Arteria not already owned by IFM.
- The offer price is A$4.75 cash per security, with a provision to increase to A$5.10 per security if IFM's interest reaches 45% or more.
- The offer includes certain 'best and final' statements.
- The Takeover Offer is conditional on third-party consents, approvals, or waivers.
- Atlas Arteria will establish an Independent Board Committee to evaluate the offer.
- Shareholders are advised to take no action until further notice.
- UBS and Flagstaff are appointed as financial advisers, and Mallesons as legal adviser for the Offer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| DroneShield Limited (DRO) ORDINARY FULLY PAID |
Industrials |
$2,444 |
Notice of Annual General Meeting/Proxy Form
|
27 Apr 2026 10:08AM |
$3.690 |
$2.645 |
fallen by
28.32%
|
|
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$100 |
March 2026 Quarterly Activities Report & Appendix 4C
|
27 Apr 2026 10:07AM |
$0.225 |
$0.170 |
fallen by
24.44%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 3 Knee OA Trial milestone achieved with 50% patient dosing.
- Interim analysis results are targeted for approximately August 2026.
- Global expansion of clinical trial sites, including Hong Kong and Moldova.
- Strong cash position with A$11.3 million in cash and equivalents.
- Additional funding from convertible note facilities and placements.
- Research collaboration with the University of London on PPS effects.
- Scientific publications support iPPS treatment efficacy and mechanism.
- Maintained focus on data quality and protocol integrity in the trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$100 |
Proposed issue of securities - PAR
|
27 Apr 2026 10:06AM |
$0.225 |
$0.170 |
fallen by
24.44%
|
|
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$100 |
Proposed issue of securities - PAR
|
27 Apr 2026 10:06AM |
$0.225 |
$0.170 |
fallen by
24.44%
|
|
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$100 |
Upsized $14M Placement Extends Runway Post IA
|
27 Apr 2026 10:05AM |
$0.225 |
$0.170 |
fallen by
24.44%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Paradigm Biopharmaceuticals Limited successfully completed a $14.0 million placement.
- The placement was upsized due to strong investor demand from an initial $8.0 million target.
- A Share Purchase Plan (SPP) was launched to raise an additional $2.0 million.
- The capital raising improves the company's balance sheet and provides funding flexibility.
- Pro forma cash post-placement is approximately $45 million, excluding option exercises.
- Funds raised will support the Phase 3 clinical trial PARA_OA_012, NDA activities, and other costs.
- Attaching Options will be issued, allowing potential for additional funding if exercised.
- Paradigm aims for non-dilutive funding opportunities post-interim analysis through partnerships or licensing.
- The Phase 3 trial PARA_OA_012 is for osteoarthritis treatment using pentosan polysulfate sodium (iPPS).
- The interim analysis for Phase 3 trial is expected in Q3 CY2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flynn Gold Limited (FG1) ORDINARY FULLY PAID |
Materials |
$13 |
March 2026 Quarterly Activities Report and Appendix 5B
|
27 Apr 2026 10:03AM |
$0.025 |
$0.021 |
fallen by
16%
|
|
FG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade mineralization at Henty Silver-Lead-Zinc Project.
- Successful re-sampling at Firetower Tungsten-Gold Project.
- Significant tungsten-bismuth anomalies at Warrentinna Project.
- Net cash outflow from operating activities.
- Sale of non-core projects in Western Australia.
- Potential gold processing hub at Golden Ridge.
- Continued exploration activities across Tasmania.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Eden Innovations Ltd (EDE) ORDINARY FULLY PAID |
Energy |
$76 |
Cleansing notice
|
27 Apr 2026 9:57AM |
$0.190 |
$0.125 |
fallen by
34.21%
|
|
| Atomos Limited (AMS) ORDINARY FULLY PAID |
Consumer Discretionary |
$19 |
Completion of Flanders Scientific acquisition
|
27 Apr 2026 9:56AM |
$0.024 |
$0.013 |
fallen by
47.92%
|
|
| 4DS Memory Limited (4DS) ORDINARY FULLY PAID |
Information Technology |
$23 |
Suspension from Quotation
|
27 Apr 2026 9:52AM |
$0.011 |
$0.011 |
fallen by
0%
|
|
| Cauldron Energy Limited (CXU) ORDINARY FULLY PAID |
Energy |
$204 |
CXU receives two WA Govt EIS grants
|
27 Apr 2026 9:51AM |
$0.052 |
$0.100 |
risen by
92.31%
|
|
CXU - Price-sensitive ASX Announcement
Full Release
Key Points
- Cauldron Energy awarded two Exploration Incentive Scheme (EIS) grants by the WA Government.
- Grants total up to $217,750, including additional funds for increased costs.
- Grants will be used for geophysical and drilling activities at Yanrey Uranium Project.
- Yanrey Project is highly prospective with several defined uranium deposits.
- The grants recognize the importance of uranium exploration to WA's economy.
- The grant will support further seismic surveying and exploration drilling.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$716 |
Weekly Estimated NTA as at 24 April 2026
|
27 Apr 2026 9:51AM |
$2.820 |
$2.720 |
fallen by
3.55%
|
|
| EBR Systems Inc (EBR) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$171 |
Correction of Issued Capital Following Share Consolidation
|
27 Apr 2026 9:51AM |
$0.650 |
$0.380 |
fallen by
41.54%
|
|
| Viking Mines Limited (VKA) ORDINARY FULLY PAID |
Materials |
$24 |
CONCEPTUAL PROCESS ESTABLISHED FOR LINKA TUNGSTEN PROJECT
|
27 Apr 2026 9:50AM |
$0.014 |
$0.010 |
fallen by
28.57%
|
|
VKA - Price-sensitive ASX Announcement
Full Release
Key Points
- Conceptual process flow diagram finalized with Mineral Technologies.
- Modular design for future integration of advanced recovery stages.
- Processing rate of 43 tonnes per hour considered for evaluation.
- Preliminary equipment sizing and procurement strategies underway.
- Project aligns with Viking's 'Rapid-Start' development strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Pause in Trading
|
27 Apr 2026 9:49AM |
$4.330 |
$5.100 |
risen by
17.78%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Temporary trading pause for Atlas Arteria
- Security Code: ALX
- Pending further announcement
- Managed by ASX Listings Compliance
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$1,510 |
Orphan Drug Designation Granted for RP11 by EMA
|
27 Apr 2026 9:48AM |
$1.295 |
$1.535 |
risen by
18.53%
|
|
| BPH Global Ltd (BP8) ORDINARY FULLY PAID |
Health Care |
$5 |
Appointment of Chief Scientific Officer
|
27 Apr 2026 9:47AM |
$0.002 |
$0.002 |
fallen by
0%
|
|